Evaluation of the effectness of kestose in unresectable pancreatic cancer

JRCT ID: jRCTs041200109

Registered date:10/03/2021

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: unresectable pancreatic cancer
• Date of first enrollment: 10/03/2021
• Target sample size: 40
• Study type: Interventional
• Intervention(s): assignment to kestose-administered and non-administered groups

Outcome(s)

• Primary Outcome: Improvement of tumor markers and nutritional status in blood tests due to increased effectiveness of insurance treatment for pancreatic cancer with improvement of nutritional status 4, 8 and 12 weeks after administration of kestose with biological marker score.
• Secondary Outcome: As the nutritional status improved 4, 8 and 12 weeks after the administration of kestose with an anatomical marker score, the effect of insurance treatment for pancreatic cancer increased and the tumor shrinkage rate improved by CT images.

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: < 80age old
• Gender: Both
• Include criteria: 1. Patients who have received sufficient explanation before participating in this study, and have obtained written consent by their own free will with sufficient understanding. 2. Patients aged 20 to 80 at the time of consent. 3. Patients diagnosed with pancreatic cancer based on the diagnostic criteria for pancreatic cancer. 4. Patients with ECOG Performance Status (PS) 0-1.

Exclude criteria

1. Patients who have previously undergone gastrointestinal surgery.
2. Patients who have been receiving radiation therapy or chemotherapy.
3. Other patients who are judged to be inappropriate by the investigator and the investigator.

Related Information

• Primary Sponsor: Hirooka Yoshiki
• Secondary Sponsor: Ohno Eizaburo